Latest Lead News

Nova Eye Medical has completed a $6.6 million placement to fund growth initiatives, supported by strong global sales growth and a major shareholder commitment. The capital raise aims to bolster sales teams and product development as the company targets profitability in its glaucoma division.

Geopacific Resources has successfully raised $40 million through a renounceable entitlement offer to advance its 1.67 million ounce Woodlark Gold Project, with a major drilling campaign and updated feasibility study planned for 2025.

Golden Mile Resources reports exceptional assay results from its Pearl Copper Project in Arizona, prompting an expansion of its maiden drilling program to include the Ford Prospect. The company also secures over $1.3 million in funding and establishes a US subsidiary to advance exploration.

Kingston Resources delivered robust production and revenue growth at Mineral Hill in Q4 2024, while advancing a strategic review of its Misima Gold Project to unlock further value.

AustChina Holdings Limited has requested a voluntary suspension of its shares as it prepares to announce a significant acquisition, extending a prior trading halt to ensure orderly disclosure.

4DS Memory Limited reports successful testing of its 60nm memory cells and progresses toward 20nm technology, alongside a $6 million capital raise and a new design partnership with Infineon.

Red Metal Limited's December 2024 quarterly report reveals a landmark rare earth discovery at its Sybella Project, alongside advancing multiple base metals and gold targets across Australia. The company is progressing towards a mine scoping study while preparing for further drilling and metallurgical testing in 2025.

Tasman Resources has identified six promising drill targets at its Parkinson Dam gold project in South Australia, supported by advanced geophysical analysis and a new high-resolution gravity survey. The company also highlights ongoing investment in Eden Innovations and strategic funding moves.

Tartana Minerals reports robust copper sulphate sales and completes a significant acquisition, positioning itself as a leading explorer and developer in Far North Queensland.

Prescient Therapeutics has secured FDA clearance to initiate its Phase 2 PTX-100 trial for relapsed cutaneous T-cell lymphoma, alongside progress in its cell therapy platforms and a solid cash position bolstered by a recent R&D rebate.

Invion Limited has marked significant progress in its cancer treatment pipeline, dosing the first patient in a pivotal skin cancer trial and reporting encouraging prostate cancer results, while securing fresh funding to support ongoing development.

Gibb River Diamonds secures key agreements to progress gold mining at Edjudina and gains international exposure for its Ellendale Diamond Project, positioning itself for growth across multiple mineral fronts.